Table 1.
Demographic characteristics
| Sociodemographic characteristics | Control group (n = 24) | Intervention group (n = 24) |
|---|---|---|
| Mean (SD) age (years) | ||
| Breast cancer | 57.5 (11.6) | 55.9 (11.0) |
| Colorectal cancer | 69.8 (9.4) | 66.0 (12.0) |
| Sex | ||
| Female | 18 | 19 |
| Male | 6 | 5 |
| Diagnosis | ||
| Breast cancer | 12 | 12 |
| Colorectal cancer | 12 | 12 |
| Chemotherapy regimen at time of inclusion | ||
| Cap (monotherapy) | 11 | 12 |
| Cap Vin | 3 | 0 |
| Cap EC | 1 | 0 |
| Cap Pac | 1 | 2 |
| Cap Beva | 3 | 2 |
| Cap Ox | 3 | 4 |
| Cap Beva Ox | 2 | 0 |
| Cap Beva Iri | 0 | 1 |
| Cap Iri Cet | 0 | 1 |
| Cap Lap | 0 | 2 |
| Median (range) no. of additional medicationsa | ||
| Breast cancer | 4 (1–10) | 5 (2–15) |
| Colorectal cancer | 3.5 (0–8) | 7 (1–13) |
| Median (range) days monitored | ||
| Breast cancer | 64 (13–119) | 104 (9–119) |
| Colorectal cancer | 73 (21–128) | 118 (31–138) |
| Median (range) number of completed cycles | ||
| Breast cancer | 2.5 (0–6) | 4.0 (0–6) |
| Colorectal cancer | 2.5 (1–6) | 4.0 (1–5) |
Cap capecitabine, Vin vinorelbine, EC epirubicin + cyclophosphamide, Pac paclitaxel, Beva bevacizumab, Ox oxaliplatin, Iri irinotecan, Cet cetuximab, Lap lapatinib
aAt time of inclusion